1PLIML J,SORM F.Synthesis of 2-deoxy-D-ribofuranosyl-5-azacytosine[J].Coll Czech Chem Commun,1964,29:2576 -2577.
2PISKALA A,SYNACKOVA M,TOMANKOVA H,et al.Direct synthesis of 5-azapyridine 2'-deoxy-ribonucleosides.Hydrolysis of 5-aza-2'-deoxycytidine[J ].Nucl Acid Res,1978,54:109-113.
3CREUSOT F,ACS G,CHRISTMAN J K.Inhibition of DNA methyltransferase and induction of friend erythroleukemic cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine[J].J Biol Chem,1982,257:2041.
2CASHEN A,SHAH A, HELGET A,et al. A phase Ⅰ pharmacokinetie trial of decitabine administered as a 3-hour infusion to patientswith acute myelogenous leukemia(AML) or myelodysp lastic syndrome (MDS) [ J ]. Blood ( ASH Annual Meeting Abstracts), 2005,106 : Abstract 1854.
3LUBBERT M, DASKALAKIS M, KUNZMANN R ,et al. Nonelonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine(decitabine) [ J ]. Leuk Res, 2004,28(12) :1267 - 1271.
4KANTARJIAN H, ISSA JP, ROSENFELD CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study [ J ]. Cancer, 2006, 106 ( 8 ) : 1794 - 1803.
5RUTER B, WIJERMANS PW, LUBBERT M. Results of 5-aza-2'- deoxycytidine retreatment in high-risk myelodysplasia patients [ J ]. Cancer,2006,106 ( 8 ) : 1744 - 1750.
6STONE MR. Are new agents really making a difference in MDS? [ J ]. Res Clin Haematol, 2008,21 (4) :639 - 646.
